Publications by authors named "S Monticone"
Extracellular vesicles (EVs) offer valuable diagnostic and prognostic insights for cardiovascular (CV) diseases, but the influence of age-related chronic inflammation ("inflammaging") and sex differences on EV profiles linked to CV risk remains unclear. This study aimed to use EV profiling to predict age and stratify patients by CV risk. We developed an EVaging index by analyzing surface antigen profiles of serum EVs from 625 participants, aged 20 to 94 years, across varying CV risk groups.
View Article and Find Full Text PDFArticle Synopsis
- Hyperkalemia is a common electrolyte imbalance, impacting around 7.3% of patients with hypertension, often due to medications or chronic kidney disease.
- A small percentage (0.04%) of these patients had familial hyperkalemic hypertension (FHH), with higher prevalence in those with unexplained hyperkalemia.
- Hyperkalemia is linked to increased cardiovascular risks, emphasizing the need for early diagnosis and tailored treatment strategies for effective management.
Article Synopsis
- Primary aldosteronism (PA) is a leading cause of high blood pressure, and the study aimed to assess the effectiveness of a new testing method (ADRR) for diagnosing PA compared to the traditional method (ARR).
- The research involved 1110 patients, discovering that 90 were diagnosed with PA, and found a strong correlation in aldosterone measurements between the two tests.
- The ADRR method proved to be accurate, achieving a sensitivity of 91% and specificity of 85%, making it a reliable option for diagnosing PA alongside the established RIA method.
Background: About 10% of patients with arterial hypertension have a positive screening test for primary aldosteronism (PA) and 50% to 70% of them have a negative confirmatory test: the appropriate follow-up of these patients is currently unknown. We investigated the incidence of PA in patients with previous negative confirmatory testing, after at least a 2-year follow-up.
Methods: One hundred eighty-four patients with a previously elevated aldosterone-to-renin ratio followed by a negative confirmatory test were recruited in 2 hypertension centers (Torino and Munich).
Background And Aims: Bempedoic Acid (BA) is a novel Lipid-Lowering Therapy (LLT). We performed a systematic review and meta-analysis to assess the efficacy and safety of BA in patients with hypercholesterolemia.
Methods: PubMed, Scopus, and Cochrane library databases were searched for randomised controlled trials evaluating the efficacy and/or safety of BA compared with placebo.